Spark Therapeutics sells priority review voucher for $110M

Spark Therapeutics (ONCE) announced it has entered into an agreement to sell its rare pediatric disease priority review voucher, or PRV. The PRV was received when LUXTURNA was approved by the FDA. Under the PRV program, a sponsor who receives FDA approval for a rare pediatric disease drug or biologic may qualify for a voucher to be redeemed at a future time for priority review of a subsequent marketing application for a different product. Per the terms of the agreement with Jazz Pharmaceuticals (JAZZ), Spark Therapeutics will receive $110M upon closing of the transaction, which is subject to customary closing conditions

https://bit.ly/2jg3EG5